DK1966368T3 - RNAi-MEDIERET INHIBERING AF IGF-1R TIL BEHANDLING AF OKULAR ANGIOGENESE - Google Patents

RNAi-MEDIERET INHIBERING AF IGF-1R TIL BEHANDLING AF OKULAR ANGIOGENESE

Info

Publication number
DK1966368T3
DK1966368T3 DK06840364.1T DK06840364T DK1966368T3 DK 1966368 T3 DK1966368 T3 DK 1966368T3 DK 06840364 T DK06840364 T DK 06840364T DK 1966368 T3 DK1966368 T3 DK 1966368T3
Authority
DK
Denmark
Prior art keywords
rnai
igf
treatment
mediated inhibition
ocular angiogenesis
Prior art date
Application number
DK06840364.1T
Other languages
English (en)
Inventor
Jon E Chatterton
David P Bingaman
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Application granted granted Critical
Publication of DK1966368T3 publication Critical patent/DK1966368T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06840364.1T 2005-12-29 2006-12-29 RNAi-MEDIERET INHIBERING AF IGF-1R TIL BEHANDLING AF OKULAR ANGIOGENESE DK1966368T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75479605P 2005-12-29 2005-12-29
PCT/US2006/062750 WO2007076548A2 (en) 2005-12-29 2006-12-29 RNAi-MEDIATED INHIBITION OF IGFlR FOR TREATMENT OF OCULAR ANGIOGENESIS

Publications (1)

Publication Number Publication Date
DK1966368T3 true DK1966368T3 (da) 2012-09-17

Family

ID=38218895

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06840364.1T DK1966368T3 (da) 2005-12-29 2006-12-29 RNAi-MEDIERET INHIBERING AF IGF-1R TIL BEHANDLING AF OKULAR ANGIOGENESE

Country Status (16)

Country Link
US (2) US20070275922A1 (da)
EP (2) EP1966368B1 (da)
JP (2) JP2009522312A (da)
KR (1) KR20080082655A (da)
CN (1) CN101326282A (da)
AU (1) AU2006330435C1 (da)
BR (1) BRPI0620723A2 (da)
CA (1) CA2632690C (da)
CY (1) CY1113098T1 (da)
DK (1) DK1966368T3 (da)
ES (1) ES2392185T3 (da)
PL (1) PL1966368T3 (da)
PT (1) PT1966368E (da)
RU (1) RU2008130901A (da)
WO (1) WO2007076548A2 (da)
ZA (1) ZA200805601B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
WO2010042751A2 (en) * 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
CN102727513B (zh) * 2011-04-15 2014-07-09 百奥迈科生物技术有限公司 靶向于组织因子基因的小核酸及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078341A1 (en) * 1999-06-21 2000-12-28 Murdoch Childrens Research Institute A method for the prophylaxis and/or treatment of medical disorders
US20050164966A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
GB0212303D0 (en) * 2002-05-28 2002-07-10 Isis Innovation Molecular targetting of IGF-1 receptor
US20040086860A1 (en) * 2002-10-04 2004-05-06 Muhammad Sohail Methods of producing RNAs of defined length and sequence
CA2515484C (en) * 2003-02-11 2011-09-20 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
US7803781B2 (en) * 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
ATE514434T1 (de) * 2004-02-25 2011-07-15 Dana Farber Cancer Inst Inc Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum

Also Published As

Publication number Publication date
BRPI0620723A2 (pt) 2011-11-22
US20140364480A1 (en) 2014-12-11
ES2392185T3 (es) 2012-12-05
AU2006330435C1 (en) 2014-03-06
EP1966368A4 (en) 2010-10-06
HK1117873A1 (en) 2009-01-23
CY1113098T1 (el) 2016-04-13
JP2009522312A (ja) 2009-06-11
WO2007076548A2 (en) 2007-07-05
WO2007076548A3 (en) 2008-04-17
PT1966368E (pt) 2012-11-02
AU2006330435B2 (en) 2013-08-22
JP2012254095A (ja) 2012-12-27
ZA200805601B (en) 2009-12-30
US20070275922A1 (en) 2007-11-29
CN101326282A (zh) 2008-12-17
EP2527443A3 (en) 2013-02-20
EP1966368A2 (en) 2008-09-10
CA2632690A1 (en) 2007-07-05
CA2632690C (en) 2015-01-13
PL1966368T3 (pl) 2013-03-29
EP2527443A2 (en) 2012-11-28
KR20080082655A (ko) 2008-09-11
EP1966368B1 (en) 2012-08-22
RU2008130901A (ru) 2010-04-10
AU2006330435A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2431359T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK1720571T3 (da) Fremgangsmåde til behandling af hæmolytisk sygdom
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
DK1730119T3 (da) Imidazolforbindelser til behandling af neurodegenerative forstyrrelser
DK2114886T3 (da) Fremgangsmåde til fremstilling af visse substituerede sulfiliminer
DK1874821T3 (da) Kombination af antistoffer med glykokortikoider til behandling af kræft
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK1801108T3 (da) Morpholinforbindelser til behandling af inflammationer.
DK2285416T3 (da) Konjugat til behandlingen af mesotheliom